1. Home
  2. ACHV

as 07-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Nasdaq

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

Founded: N/A Country:
Canada
Canada
Employees: N/A City: SEATTLE
Market Cap: 159.0M IPO Year: N/A
Target Price: $14.00 AVG Volume (30 days): 454.7K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.27 EPS Growth: N/A
52 Week Low/High: $3.03 - $5.98 Next Earning Date: 08-12-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

ACHV Daily Stock ML Predictions

Stock Insider Trading Activity of Achieve Life Sciences Inc. (ACHV)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Stewart Richard Alistair ACHV Executive Chairman Mar 4 '24 Buy $4.59 10,000 $45,850.00 38,501 SEC Form 4
Bencich John ACHV CEO Mar 4 '24 Buy $4.59 10,000 $45,850.00 76,724 SEC Form 4

Share on Social Networks: